| instructions for use |
|---|
CD134/OX40 is a receptor of OX40 ligand (OX40L) transactivated by Tax of HTLV-1. OX40 is expressed in activated CD4+ and CD8+ T cells. OX40 on activated T cells has a role in proliferation of T cells and production of cytokines by binding with OX40L expressed on antigen presenting cells like dendritic cells or activated B cells. In addition, it is also involved in activated T cell invasion to sites of inflammation through the binding with OX40L.
It has been observed that soluble CD134 / OX40 in plasma is significantly higher in acute adult T-cell leukemia patients compare to HTLV-1 carriers and healthy individual in recent study. It has also been reported that HTLV-1 gene (number of copies) in peripheral blood lymphocytes was correlated with soluble OX40 level in plasma of HTLV-1 infected patients. (See reference below)
*distributed by IBL International
For concrete data please consult the Instruction for Use in the download box on the top right side.
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
At Tecan, we are driven to improve people’s lives and health.
